Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gliclazide
|
| gptkbp:administeredBy |
oral
|
| gptkbp:affiliatedWith |
gptkb:sulfonylurea
|
| gptkbp:approvedBy |
many countries
|
| gptkbp:availableOn |
Diamicron MR
|
| gptkbp:brand |
gliclazide
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:manufacturer |
gptkb:Servier
|
| gptkbp:notRecommendedFor |
gptkb:diabetic_ketoacidosis
type 1 diabetes |
| gptkbp:sideEffect |
gptkb:hypoglycemia
weight gain |
| gptkbp:usedFor |
gptkb:type_2_diabetes
|
| gptkbp:bfsParent |
gptkb:Servier_Laboratories
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Diamicron
|